ESSA Pharma to Present at the Jefferies Global Healthcare Conference

5/30/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EPIX alert in real time by email

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 30, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 p.m. ET in New York.

David. R. Parkinson, President, and Chief Executive Officer and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings.

A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com, and follow us on Twitter and LinkedIn.

Contacts

ESSA Pharma, Inc.

Peter Virsik, Chief Operating Officer

778.331.0962

[email protected]

Investors and Media:

Argot Partners

212.600.1902

essa@argotpartners.com

View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-present-at-the-jefferies-global-healthcare-conference-302158625.html

SOURCE ESSA Pharma Inc

Get the next $EPIX alert in real time by email

Date

Price Target

Rating

Analyst

11/4/2024

Buy → Hold

Jefferies

11/4/2024

Outperform → Perform

Oppenheimer

11/4/2024

$15.00 → $2.00

Overweight → Neutral

Piper Sandler

6/26/2023

$17.00

Outperform

Oppenheimer

8/17/2021

$36.00 → $22.00

Outperform

Oppenheimer

ESSA Pharma to Present at the Jefferies Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$EPIX

$EPIX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Parkinson David Ross bought $21,213 worth of shares (9,223 units at $2.30), increasing direct ownership by 16% to 65,675 units (SEC Form 4)

Berger Franklin M bought $133,274 worth of shares (23,259 units at $5.73), increasing direct ownership by 3% to 784,404 units (SEC Form 4)

Berger Franklin M bought $419,661 worth of shares (76,471 units at $5.49), increasing direct ownership by 11% to 760,875 units (SEC Form 4)

ESSA Pharma to Present at the Jefferies Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $EPIX

$EPIX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Parkinson David Ross bought $21,213 worth of shares (9,223 units at $2.30), increasing direct ownership by 16% to 65,675 units (SEC Form 4)

Berger Franklin M bought $133,274 worth of shares (23,259 units at $5.73), increasing direct ownership by 3% to 784,404 units (SEC Form 4)

Berger Franklin M bought $419,661 worth of shares (76,471 units at $5.49), increasing direct ownership by 11% to 760,875 units (SEC Form 4)

Recent Analyst Ratings for
$EPIX

$EPIX
Insider Purchases